Skip to content

Clinical study on the therapeutic effect of Juanbi Qianggu Formula combined with DMARDs on Rheumatoid Arthritis with liver and kidney deficiency

Clinical study on the therapeutic effect of Juanbi Qianggu Formula combined with DMARDs on Rheumatoid Arthritis with liver and kidney deficiency

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004848
Enrollment
Unknown
Registered
2021-05-15
Start date
2021-05-15
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

Sponsors

Shanghai Guanghua Integrated traditional Chinese and Western Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Agree to participate in this study and sign an informed consent form; 2. Comply with the diagnostic criteria for rheumatoid arthritis stipulated in the classification standards of the American College of Rheumatology (ACR) in 1987 and the Chinese Medicine Industry Standards of the Peoples Republic of China "Diagnosis and Efficacy Standards for Diseases and Symptoms of Traditional Chinese Medicine" (ZY/T001.1-94) and " Practical TCM Rheumatology" (edited by Wang Chengde, Shen Pi'an, Hu Mengqi, People's Medical Publishing House, 2009) TCM "Liver and Kidney Deficiency Type" Kaibi Syndrome Differentiation Standard; 3. DAS28 score = 6 points.

Exclusion criteria

Exclusion criteria: 1. Abnormal liver and kidney function; 2. Pregnant women or breastfeeding women, mental patients; 3. Patients with serious diseases such as heart, liver, brain, kidney and hematopoietic system; 4. Overlap other rheumatic diseases such as systemic lupus erythematosus, Sjogrens syndrome, severe knee osteoarthritis ; 5. Patients with advanced stage, severe joint deformity, and grade IV joint function; 6. Those who have received other study drugs 3 months before screening; 7. Those who are unable or unwilling to provide informed consent or unable to comply with the test requirements; 8. Researchers believe that it is not suitable for all subjects participating in this study.

Design outcomes

Primary

MeasureTime frame
C-reactive protein;Cellular inflammatory factor;Blood routine;Erythrocyte sedimentation rate;

Countries

China

Contacts

Public ContactXiao Lianbo

Shanghai University of traditional Chinese Medicine

13701888178@163.com+86 13701888178

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026